[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myelin-oligodendrocyte-glycoprotein-mog-antibody-related-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myelin-oligodendrocyte-glycoprotein-mog-antibody-related-disorders":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100354845","french-registry-for-monitoring-pregnancies-for-multiple-sclerosis-100354845",false,"NCT03900221","French Registry for Monitoring Pregnancies for Multiple Sclerosis","French Registry for Monitoring Pregnancies and Children of Women With Multiple Sclerosis Within The Observatoire Français de la Sclérose en Plaque (OFSEP) Cohort","RESPONSE","Inclusion Criteria:\n\n* All groups of patients eligible to participate to the Observatoire Français de la Sclérose en Plaque (OFSEP), including :\n* Definite Multiple sclerosis (MS) according to McDonald criteria\n* Whatever the clinical course (single attack MS, relapsing-remitting MS, secondary progressive MS, primary progressive MS)\n* Radiologically Isolated Syndromes (RIS) (will be validated by the RIS expert group)\n* Clinically Isolated Syndromes (CIS)\n* Neuromyelitis optica (NMO) and NMO spectrum disorders (will be validated by the \"Neuro-optico-myélite aiguë de Devic et des syndromes neurologiques apparentés\" (NOMADMUS) expert group)\n* No age limit (patients under the age of 18 might be included, provided informed consent is obtained from the parents)\n* Ongoing pregnancy: there will be no limit in the gestational age at inclusion. Women can be included at any time before delivery, but the gestational age at inclusion will be recorded and introduced in the analyses whenever pertinent. However, neurologists and patients will be encouraged to start the study as soon as pregnancy is diagnosed.\n* Able to give informed consent\n* Able to read and\u002For understand French\n\nExclusion Criteria:\n\n* None","ALL",{"count":19,"type":20},1500,"ESTIMATED","7 Years","OBSERVATIONAL","The influence of pregnancy on the course of multiple sclerosis (MS) has long been a controversial topic. After the publication of the first large prospective study of pregnancy and MS in 1998, counselling of women with MS has radically changed and many patients have been able to fulfill their desire of motherhood. However, there are still some challenges for the neurologist, who has to face old unanswered questions or new issues, regarding the use of disease modifying drugs (DMDs) in this period of life, effects on the short and long term outcome of the mother (in terms of relapses and disability) and the child, role of breast-feeding and locoregional analgesia.\n\nTo set up a national prospective pregnancy registry for patients with MS, nested within the Observatoire Français de la Sclérose en Plaque (OFSEP) cohort, owing to a better knowledge of interactions between MS and pregnancy-related issues (pregnancy itself, locoregional analgesia, breastfeeding, impact of using or stopping DMDs on women\u002Fchildren…)",[25,26,27,28],"Sclerosis, Multiple","Neuromyelitis Optica Spectrum Disorder","Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders","Pregnancy Abnormal",[30,31,32,33,34],"Multiple sclerosis","pregnancy","disease modifying drugs","breastfeeding","loco-regional analgesia","RECRUITING","2025-12-30",{"date":38,"type":39},"2026-01-05","ACTUAL",{"date":41,"type":39},"2019-08-12",{"date":43,"type":20},"2036-08-12",{"name":45,"class":46},"Hospices Civils de Lyon","OTHER",48,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":22,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100563576","evaluation-of-two-cell-based-assays-for-diagnosing-mog-igg-associated-disorders-100563576","NCT06617962","Evaluation of Two Cell-based Assays for Diagnosing MOG-IgG Associated Disorders","Evaluation of The Diagnostic Value of Two Cell-based Assays for MOG-IgG-associated Diseases: A Multicenter, Paired Design Observational Study","Inclusion Criteria:\n\n* age ≥18 years old, male and female.\n* MOGAD is highly suspected.\n* Other inflammatory CNS disease control groups include: According to the diagnostic criteria and consensus of various diseases, the diagnosis of multiple sclerosis, Autoimmune encephalitis (except NMDAR encephalitis), Guillain-Barre syndrome (GBS), Chronic Inflammatory Demyelinating polyradiculopathy (CIDP), Retinal Cerebrovascular disease (SUSAC), POEMS syndrome (POEMS), and neuropathy were confirmed. The monoclonal gammopathy of unknown significance (MGUS), Sarcoidosis and so on.\n* The control group of non-inflammatory central nervous system diseases included: Migraine, CSVD, benign cranial hypertension, Glioma with definite diagnosis and no other autoimmune diseases.\n* Healthy controls include healthy people who have no autoimmune diseases through physical examination and other means.\n* Complete clinical data.\n* Informed consent of the patient or his guardian has been obtained.\n\nExclusion Criteria:\n\n* According to the Guidelines for Diagnosis and Treatment of Optic Neuromyelitis Spectrum Diseases (2021), patients with optic Neuromyelitis Spectrum diseases (NMOSD) with positive AQP4 were clearly diagnosed.\n* According to the Expert Consensus on the Diagnosis and Treatment of Autoimmune encephalitis in China (2022), the diagnosis was confirmed as NMDAR encephalitis.\n* Patients with positive anti-glial fibrillary acidic protein antibody (GFAP-IgG) in serum and\u002For cerebrospinal fluid.\n* Lack of clinical data.\n* Unqualified blood samples.\n* The patient\\'s informed consent was not obtained.\n* Misdiagnosis in the research process went wrong in this study.",true,"18 Years",{"count":58,"type":20},240,"30 Days","Anti-myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD) is a rare inflammatory autoimmune disease. In addition, since the international MOGAD group proposed live-cell based assays for MOGAD diagnosis in 2023, there are still no real-world cohort validation studies on this methodology. This study intends to establish a large sample cohort with multi-center and paired design. MOG-IgG detection based on live cells and fixed cells was performed on the study participants with high suspicion of MOGAD and the negative control population, to obtain the diagnostic performance parameters and consistency evaluation of the two methodologies, evaluate their clinical diagnostic value, and explore the best individual assay cutoffs for MOG-IgG detection suitable for the diagnosis of MOGAD in China.",[27],"2025-09-29",{"date":64,"type":39},"2025-10-01",{"date":66,"type":39},"2024-11-18",{"date":68,"type":20},"2025-12-01",{"name":70,"class":46},"Huashan Hospital",1]